Navigator Equity Solutions SE: Strategische Neuausrichtung auf Immobilieninvestments in Europa mit erstem Fokus auf Wohnimmobilien in Dublin pressetext.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pressetext.com Daily Mail and Mail on Sunday newspapers.
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
Companies enter into a collaboration and services agreement / Bayer to support CureVac in numerous areas, including development and supply of CVnCoV / CureVac benefits from Bayer´s expertise and established infrastructure / Plan to facilitate the supply of several hundred million doses
Berlin and Tübingen, Germany / Boston, USA, January 7, 2021 – Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac´s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its expertise and established infrastructure in areas such as clinical operations, regulatory affairs, pharmacovigilance, medical information, supply chain
DGAP-News: CureVac / Key word(s): Alliance/Agreement
CureVac : CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
07.01.2021 / 08:30
CureVac and Bayer join forces on COVID-19 vaccine candidate CVnCoV
- Companies enter into a collaboration and services agreement
- Bayer to support CureVac in numerous areas, including development and supply of CVnCoV
- CureVac benefits from Bayer s expertise and established infrastructure
- Plan to facilitate the supply of several hundred million doses
Berlin and Tübingen, Germany/ Boston, USA, January 7, 2021 -
Bayer has signed a collaboration and services agreement with CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA). Under the terms of the agreement, Bayer will support the further development, supply and key territory operations of CureVac s COVID-19 vaccine candidate CVnCoV. To this end, Bayer will contribute its exper
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
MEDIROM Healthcare Technologies Inc. Announces Closing of $12,000,000 Initial Public Offering
MEDIROM Healthcare Technologies Inc.December 31, 2020 GMT
NEW YORK, Dec. 31, 2020 (GLOBE NEWSWIRE) MEDIROM Healthcare Technologies Inc. (NasdaqCM:MRM), a holistic healthcare company from Japan (the “Company”), announced today that it has closed its previously announced initial public offering of 800,000 ADSs at a price to the public of US$15.00 per share. Each ADS represents one share of the Company’s common stock. After underwriting discounts and offering expenses, the Company expects to receive net proceeds of approximately US$7.8 million.
30 december 2020 kl 08:01
Working with the UK government, first vaccinations to begin early in the New Year
Regulatory interactions continue around the world for next approvals
AstraZeneca s COVID-19 vaccine has been approved for emergency supply in the UK, with the first doses being released today so that vaccinations may begin early in the New Year.
The UK Medicines and Healthcare products Regulatory Agency (MHRA) has provided authorisation for emergency supply of COVID-19 Vaccine AstraZeneca, formerly AZD1222, for the active immunisation of individuals 18 years or older. The authorisation recommends two doses administered with an interval of between four and 12 weeks. This regimen was shown in clinical trials to be safe and effective at preventing symptomatic COVID-19, with no severe cases and no hospitalisations more than 14 days after the second dose.